In which countries is Isatuximab approved?

Overview of Isatuximab 

Isatuximab, marketed under the trade name SARCLISA, is an immunoglobulin G1 (IgG1) monoclonal antibody designed to target CD38, a glycoprotein highly expressed on plasma cells, including malignant cells in multiple myeloma. By binding to CD38, isatuximab can induce tumor cell death via multiple mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and in some settings, direct induction of apoptosis. This multifaceted mechanism allows it to combat plasma cell malignancies effectively and has positioned it as a critical therapeutic option in the treatment landscape for multiple myeloma. 

Clinical Indications 

Clinically, isatuximab has been primarily developed for and approved in the treatment of relapsed or refractory multiple myeloma. It is used in combination with other drugs such as pomalidomide and dexamethasone to enhance clinical outcomes in patients who have received prior lines of therapy. The clinical trials, such as the phase III ICARIA-MM study detailed in several peer-reviewed analyses, demonstrated that the addition of isatuximab improved progression-free survival in this patient population by providing additional depth of response and higher rates of minimal residual disease (MRD) negativity. These advances support its use for a subset of patients who often have limited treatment options. 

Regulatory Approval Process 

General Drug Approval Process 

Pharmaceutical products, especially first‐in‐class or innovative agents like monoclonal antibodies, undergo a rigorous process before securing market access. This process involves preclinical research, followed by phased clinical trials (Phase I, II, III) to evaluate safety, efficacy, pharmacokinetics, and pharmacodynamics. Post these trials; manufacturers submit a New Drug Application (NDA) or similar marketing applications to regional regulatory agencies. Each regulatory authority, whether in the United States, Europe, or Asia, follows well‐established guidelines based on the International Council for Harmonisation (ICH) frameworks. These guidelines ensure that the data submitted reflect robust clinical trial results, proper manufacturing practices, and comprehensive safety monitoring plans, both in controlled clinical trial settings and through post-marketing surveillance. 

Specifics for Biologics Like Isatuximab 

Biologics, by virtue of their complex manufacturing processes and mode of action, face additional layers of regulatory scrutiny. For monoclonal antibodies, the regulatory review process involves detailed evaluations of homologous recombination at the molecular level, binding kinetics, mechanism of action, and immunogenicity assessments. Agencies evaluate the totality of evidence—ranging from analytical characterization to clinical performance—to ascertain that there are no clinically meaningful differences compared to reference products where applicable. In the case of isatuximab, the submission dossier comprised data from phase I to III clinical trials that established its efficacy in relapsed and refractory multiple myeloma, alongside manufacturing quality controls that uphold safety and consistency. Notably, biologics such as isatuximab also require monitoring for post-approval adverse events since the immunogenic potential can evolve with broader real-world use. 

Isatuximab Approval by Country 

The global regulatory landscape for isatuximab is built on the achievements of several major regulatory agencies. The structured and stringent evaluation processes of agencies like the US FDA, the European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and China’s National Medical Products Administration (NMPA) provide confidence in its safety and efficacy from multiple geographical perspectives. 

North America 

In North America, the primary regulatory body is the US Food and Drug Administration (FDA). 
– The FDA granted accelerated approval to isatuximab (in combination with pomalidomide and dexamethasone) in March 2020 for the treatment of adult patients with relapsed and refractory multiple myeloma. 
– The approval was based on robust clinical trial data demonstrating improved progression-free survival and response rates in patients who had received at least two prior therapies. 
– The marketing application under reference number "761113_001" for isatuximab highlights that the formulation is intended for intravenous injection with a specific strength (100MG/5ML or 20MG/ML), underscoring both its potency and its precise dosage form. 

Although specific information on Canada is not provided in the available references, the US FDA approval is highly influential and often paves the way for similar decisions in neighboring jurisdictions. In North America, the establishment of isatuximab as a treatment for multiple myeloma represents a significant advancement, contributing to an increased portfolio of monoclonal antibody therapies approved for oncology indications. 

Europe 

In Europe, the regulatory pathway for isatuximab is managed centrally by the European Medicines Agency (EMA). 
– On July 29, 2024, the EMA issued marketing authorization for isatuximab in combination with other myeloma therapies (pomalidomide plus dexamethasone), as evidenced by the drug application with the reference number "EMEA/H/C/004977". 
– Under this authorization, isatuximab is approved for use in multiple myeloma patients who have relapsed or are refractory to prior treatments. 
– The EMA’s endorsement reflects a stringent review of both the clinical trial data and the manufacturing integrity of the product, similar to the processes employed by the FDA. 
– Furthermore, European approvals typically involve a comprehensive assessment of comparative efficacy and safety data across diverse member states, ensuring that the product meets the high standards required across the European Union, thereby providing uniform access across countries such as Germany, France, Italy, and Spain. 

The European approval process for biologics, particularly those targeting complex malignancies, emphasizes both rapid patient access and the assurance of long-term safety outcomes. The EMA’s decision thus plays a pivotal role in enabling market access to innovative treatments for patients in need within the European economic area. 

Asia and Other Regions 

In Asia, regulatory approval for isatuximab has been achieved in several key markets: 

– Japan 
– In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is the regulatory authority responsible for drug approval. 
– Sanofi KK submitted the application, and the product was approved under the drug application number "30200AMX00511" on February 20, 2025. 
– The formulation in Japan is provided as "SARCLISA I.V. Infusion" with clear dosage specifics (100mg per preparation) and is tailored to meet local clinical requirements. 
– The PMDA’s evaluation assures that the Japanese population has access to cutting-edge treatments for multiple myeloma, in keeping with international standards for biologic agents. 

– China 
– In China, the regulatory oversight is provided by the National Medical Products Administration (NMPA). 
– Sanofi’s collaboration with local entities, such as Sanofi (China) Investment Co. Ltd., has resulted in the submission and subsequent approval of isatuximab under the drug application number "国药准字SJ20250001" on January 8, 2025. 
– The approval by the NMPA is a critical milestone, given the massive patient population and the increasing demand for innovative biologics in oncology. 
– The product is marketed under two trade names, “SARCLISA” and “赛可益,” which ensures that it is readily accessible in local language contexts and into the broader healthcare system across China. 

– Other Asian Regions and Beyond 
– While the provided references primarily detail approvals in Japan and China, Asia is a diverse market where regulatory harmonization is ongoing. 
– Countries such as South Korea have established robust frameworks for orphan drug designation and priority review, and although a direct reference to isatuximab’s approval in South Korea is not prominently cited in these materials, the overall landscape indicates that major innovative oncology drugs, especially from leading pharmaceutical companies such as Sanofi, are typically considered for approval in multiple Asian jurisdictions shortly after initial approvals in Japan and China. 
– Additionally, regions like Australia and parts of Asia-Pacific, which regularly adopt regulatory decisions from comparable agencies (e.g., the US FDA or EMA), might also have pathways for isatuximab approval if not already approved. However, the explicit and well-documented approvals in Japan and China serve as the prominent examples based on the current references.

Overall, the approval of isatuximab in these key territories—North America (USA), Europe (across the European Union via EMA), and Asia (specifically Japan and China)—demonstrates its global acceptance as a critical treatment for multiple myeloma. These approvals are underpinned by rigorous clinical trial data and a solid track record of performance in late-stage clinical evaluations. 

Implications of Approval Status 

Impact on Treatment Options 

The multi-regional approval of isatuximab has significant and far-reaching implications for the treatment of multiple myeloma. 
– In the United States, the FDA’s accelerated approval pathway provided early access to isatuximab for a patient group with high unmet needs. This has broadened the therapeutic landscape for relapsed and refractory multiple myeloma, offering an alternative option to patients who have exhausted other lines of therapy. 
– In Europe, the EMA’s centralized approval ensures that patients in all member states benefit from a uniform level of therapeutic efficacy and safety, assisting clinicians in making informed treatment decisions. This is particularly important in Europe where treatment guidelines are frequently updated in light of novel clinical evidence. 
– In Asia, particularly in markets like Japan and China, the approvals by the PMDA and NMPA, respectively, not only provide additional treatment options to local patient populations but also underscore the growing global emphasis on personalized medicine and the use of advanced biologics in oncology. Access to innovative biologics such as isatuximab contributes to the overall improvement of survival rates and quality of life for patients across these regions.

Furthermore, the introduction of a biologic that has met rigorous regulatory standards also bolsters confidence among healthcare providers and payers. It assures them that the therapeutic benefits are backed by solid evidence and that the manufacturing processes adhere to high-quality standards which are crucial for managing complex diseases like multiple myeloma.

Market Access and Competition 

The regulatory approvals also have substantial market and competitive implications: 
– From a market access standpoint, approval by renowned agencies such as the FDA, EMA, PMDA, and NMPA offers isatuximab a significant competitive advantage. This not only builds trust in the product’s safety and efficacy profile but also facilitates its inclusion in national healthcare formularies and reimbursement policies. 
– Market competition is further influenced by the fact that isatuximab joins the growing portfolio of anti-CD38 therapies such as daratumumab. This competitive landscape drives further innovation, encourages competitive pricing, and eventually, improves patient access by providing multiple therapeutic choices. 
– The detailed regulatory review processes ensure that parallels in safety and efficacy are maintained, which means that in addition to the original innovative biologic, biosimilar products also follow, promoting cost savings and wider access among patients in both developed and emerging markets. 
– Moreover, as regulatory agencies continue to implement expedited pathways and streamlined review mechanisms, manufacturers like Sanofi are encouraged to invest further in enhancing their biologic portfolios. This environment fosters increased collaboration between pharmaceutical companies, clinical researchers, and healthcare policymakers, ultimately leading to a dynamic market where patient-centric innovation drives continuous improvements in treatment paradigms.

The competitive edge provided by multi-regional approvals also catalyzes further research into novel combination therapies and supports the design of next-generation clinical trials. This strategic approach not only benefits patients by enhancing treatment efficacy but also contributes to the broader medical community’s understanding of multiple myeloma and its management.

Conclusion 

In summary, isatuximab has achieved regulatory approval in pivotal global markets that include: 
– In North America, it is approved in the United States by the FDA as an integral part of therapy for relapsed or refractory multiple myeloma. 
– In Europe, the European Medicines Agency (EMA) has granted marketing authorization for isatuximab (under the reference "EMEA/H/C/004977") as part of a combination therapy for multiple myeloma, ensuring uniform access across EU member states. 
– In Asia, isatuximab has received approvals in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) (as detailed under the drug application "30200AMX00511") and in China by the National Medical Products Administration (NMPA) (as evidenced by the application "国药准字SJ20250001"). 

This comprehensive regulatory acceptance not only underscores the drug’s robust clinical efficacy and safety profile but also significantly impacts the treatment options available to patients with multiple myeloma worldwide. The alignment of multiple regulatory agencies in approving isatuximab reaffirms its role as a transformative therapeutic option in the global fight against this challenging malignancy. Furthermore, the multi-regional approvals enhance market competition, promote more cost-effective treatment strategies, and catalyze further innovation in biologic therapies. Ultimately, the global approval of isatuximab represents a major step forward in improving clinical outcomes, expanding access to advanced treatments, and reinforcing the critical importance of rigorous regulatory standards in ensuring patient safety and therapeutic excellence.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.